Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | TTPA | P49638 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14580953 | 0.95 | GSTO1 (0.44) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL14612653 | 0.92 | GSTO1 (0.50) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL10346392 | 0.91 | GSTO1 (0.50) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL5773112 | 0.91 | ALOX5 (0.57) | ALOX5MEN1KMT2ANR1I2MAPT | |
| SCHEMBL5775253 | 0.88 | ALOX5 (0.48) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL10074182 | 0.86 | PSEN1 (0.64) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL5806822 | 0.84 | ALOX5 (0.57) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL5772966 | 0.81 | AKT1 (0.61) | ALOX5NR1I2 | |
| SCHEMBL9280072 | 0.80 | PSEN1 (0.52) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL16273940 | 0.79 | ALOX5 (0.56) | ALOX5MEN1KMT2ANR1I2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004045534-A2 | CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | MONSANTO TECHNOLOGY LLC | 2004-05-20 | — | — | US | claimed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2004045534-A2 | CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | MONSANTO TECHNOLOGY LLC | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | GSTO1 6/4885PTPN1 2288/4885ALOX5 150/4885 |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | GSTO1 6/4885PTPN1 2288/4885ALOX5 150/4885 |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | GSTO1 2888/4885PTPN1 4765/4885ALOX5 1992/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | GSTO1 1664/4885PTPN1 4790/4885ALOX5 1604/4885 |
| US-20040097433-A1 | Chroman derivatives for the reduction of inflammation symptoms | CCL2, MPO, MB | GSTO1 297/4885PTPN1 2387/4885ALOX5 1449/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | GSTO1 1664/4885PTPN1 4790/4885ALOX5 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.